Clincosm LogoSign in Get a demo

PLAN: Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis

Sponsor
Azienda Sanitaria ASL Avellino 2 (Other)
Overall Status
Unknown status
CT.gov ID
NCT02976688
Collaborator
(none)
15
Enrollment
1
Arm
11
Duration (Months)

Study Details

Study Description

Brief Summary

End-stage renal disease (ESRD) is associated with multiple comorbidities such as cardiovascular disease, anemia, mineral and bone disorders, malnutrition, body wasting, muscle loss (sarcopenia), neurological problems and infections resulting in a poor survival.

In the pathogenesis of the uremic syndrome the altered intestinal function seems to be an important contributor. While the normal gut microbiota plays a prominent role in the maintenance of health and disease prevention, changes of its composition is associated with numerous diseases such as obesity, type 2 diabetes, cardiovascular disturbances and auto-immune diseases.In ESRD metabolic alterations of uremia results in quantitative and qualitative changes of its bacterial flora with an overgrowth of pathobionts (1). Due to concomitant disruption of the intestinal barrier function, noxious luminal products are translocated in the body's internal milieu (2).The accumulation of these compounds correlates with systemic inflammation, protein wasting and accelerated cardiovascular complications in hemodialysis patients (3).

Short-chain fatty acids (SCFA) are produced in the colon and distal small intestine by anaerobic bacteria following fermentation of complex carbohydrates.They have been shown to exert anti-inflammatory, anti-cancer, antibacterial and antidiabetic effects (4). Supplementation of SCFA exerts anti-inflammatory actions both in intestinal epithelial cells (5) and in the cardiovascular system (6). They also positively influence auto- immune reactions /diseases (7,8).

In this study we want to investigate in MHD patients whether a treatment with SCFA in form of sodium propionate (SP) modulates the systemic inflammation, insulin resistance and accumulation of intestinal uremic toxins.

Condition or Disease Intervention/Treatment Phase
  • Other: Sodium Propionate
 Phase 2/Phase 3

Detailed Description

End-stage renal disease (ESRD) is associated with multiple comorbidities such as cardiovascular disease, anemia, mineral and bone disorders, malnutrition, body wasting, muscle loss (sarcopenia), neurological problems and infections resulting in a poor survival. Important promoters of these obstacles are enhanced generation of reactive oxygen species (ROS), systemic inflammation, acquired immunodeficiency (9, 10) and an impaired glucose and insulin homeostasis (11).

Systemic inflammation and oxidative stress in ESRD are induced by activation of the innate immune system involving monocytes, macrophages, granulocytes and cellular constituents (endothelial cell activation) as well as depletion of natural regulatory T cells that impairs their ability to suppress inflammation .The concomitant reduced humoral immunity is favored by depletion of antigen presenting dendritic cells, a lowered CD44/CD8 T cell ratio, depletion of naïve and central memory T cells, diffuse B cell lymphopenia and an impaired phagocytic ability of monocytes and PMNs (12).

Insulin resistance (IR) participates in the pathogenesis of multiple metabolic and cardiovascular disturbances (13) and is an important factor of the accelerated muscle protein degradation in ESRD (14). Underlying mechanisms of IR are the metabolic inflammation, in particular elevated LPS levels.

In the pathogenesis of the uremic syndrome the altered intestinal function seems to be an important contributor. While the normal gut microbiota plays a prominent role in the maintenance of health and disease prevention, changes of its composition is associated with numerous diseases such as obesity, type 2 diabetes, cardiovascular disturbances and auto-immune diseases. In ESRD metabolic alterations of uremia results in quantitative and qualitative changes of its bacterial flora with an overgrowth of pathobionts (1). Due to concomitant disruption of the intestinal barrier function, noxious luminal products are translocated in the body's internal milieu (Fig.2). The passage includes whole bacteria (going into mesenteric lymph nodes), endotoxins/ lipoproteinlipase (LPS) (cell wall components of the bacteria) and other noxious luminal products which induce a persistent local (gut) and systemic inflammation.The process is intensified by the intestinal generation of several pro-inflammatory uremic toxins such as indoxyl sulfate, p-cresyl sulfate and trimethyamine-N-oxide (2).The accumulation of these compounds correlates with systemic inflammation, protein wasting and accelerated cardiovascular complications in hemodialysis patients (3).

Short-chain fatty acids (SCFA) are produced in the colon and distal small intestine by anaerobic bacteria following fermentation of complex carbohydrates. The 3 major compounds are acetic acid, butyric and propionic acids. SCFA contribute to the health of the gut (microbiome and mucosa) and the host. They have been shown to exert anti-inflammatory, anti-cancer, antibacterial and antidiabetic effects. Lower values and an dysbiotic gut contribute to various diseases such colitis, type 2 diabetes, rheumatoid disease and multiple sclerosis. Supplementation of SCFA exerts anti-inflammatory actions both in intestinal epithelial cells (5) and in the cardiovascular system (6). They also positively influence auto- immune reactions /diseases (7, 8). In particular SCFA enhances formation of regulatory T cells in the colon which are critical for regulating intestinal inflammation (15). Also effector T cells such as Il-10 are implicated (16). Likewise SCFA are involved in the control of body weight and insulin sensitivity (17), cholesterol synthesis (18) and retardation of progressive CKD.

In patients on maintenance hemodialysis (MHD) a diet with a high fiber content, which favors the intestinal SCFA formation (19), lowered the plasma levels of the colon-derived solutes indoxyl sulfate and possibly p-cresol sulfate (20) and reduced inflammation, cardiovascular diseases and all-cause mortality in CKD/ESRD patients (21). However, in ESRD consumption of a fiber rich diet is limited due to the risk of hyperpotassemia. In addition the frequent antibiotic therapy, application of phosphate binder or iron therapy alters the gut microbiome.

The following mechanisms have been proposed for the actions of SCFA: the G-protein-coupled receptors GPR 41 and GPR 43 (the free fatty acid receptors FFAR 3 and 2 ), GPR 109a, Olfr78 , the inhibition of histone deacetylases (HDAC) and stimulation of histone acetyltransferase (HAT) activity (22, 23).

n this study we want to investigate in MHD patients whether a treatment with SCFA in form of sodium propionate (SP) modulates the systemic inflammation, insulin resistance and accumulation of intestinal uremic toxins. SP is chemically composed by a carboxylic acid moiety and a small hydrocarbon chain with three carbon atoms (black balls), two oxygen (red balls) and the white hydrogen atoms.

SP is involved in most effects of the short chain fatty acids including inhibition of intestinal and hepatocyte lipid synthesis (24), lowering of fasting glycemia (25, 26) and protection against diet-induced obesity ( 27). SP also regulates colonic T-reg cell homeostasis (28) and exerts marked anti-inflammatory actions including intestinal epithelial cells and macrophages (29) as well as in neutrophils, colon cells and colon cultures (30). It improved experimental autoimmune encephalomyelitis (31) and experimental acute renal failure (32). In addition antibacterial effects were documented (33, 34).

The patients under maintenance hemodialysis will receive the food additive sodium propionate with a daily intake of 2 x 500 mg in form of capsules (Propicum) for 12 weeks. The demographic information and the blood chemistry will be collected before the study, after 6, 12 and 16 weeks of drug administration.

The project will last for one year. The planned patient group should comprise of 15 patients on maintenance hemodialysis.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
15 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effects of Short-chain Fatty Acids, Here Sodium Propionate, a Metabolism Product of the Human Gut-microbiome, on Inflammatory and Metabolic Parameters in Patients on Maintenance Hemodialysis - a Pilot Study
Study Start Date :
Jan 1, 2017
Anticipated Primary Completion Date :
Jul 1, 2017
Anticipated Study Completion Date :
Dec 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Sodium propionate

Sodium propionate will be administered with a daily intake of 2 x 500 mg in form of capsules for 12 weeks.

Other: Sodium Propionate
Sodium propionate is a non-toxic food additive, confirmed and licensed by the European Food Safety Authority (EFSA) sodium propionate E281. We are planning the oral application of 500 mg SP 2x per day. This dose is about 0.014 mg/kg of the body weight. Therefore, no risk of toxicity is expected in the patients.
Other Names:
  • Sodium propionate E281

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Variation from the beginning to the study end of serum inflammatory biomarkers [16 weeks]

      endotoxin /lipopolysaccharide levels, high sensitivity C-reactive protein (hs-CRP), fibrinogen, interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), IL-10, IL-2, INFγ, TGFβ, IL-4, IL-1β, IL-17a and white blood cell count.

    2. Variation from the beginning to the study end of serum oxidative stress biomarkers [16 weeks]

      glutathione peroxidase, malone dialdehyde

    3. Variation from the beginning to the study end of insulin resistance [16 weeks]

      Determination of Homa Index (Homeostasis Model Assessment) by measurement fasting blood sugar and insulin level as well as hemoglobin HbA1c. IR appears to be as associated of metabolic disorders including lipid abnormalities, atherosclerotic cardiovascular disease and accelerated muscle protein degradation (Wang et al. 2006). IL is induced in particular by systemic inflammation.

    4. Variation from the beginning to the study end of serum lipid levels [16 weeks]

      Triglycerides, total cholesterol, high and low density cholesterol

    5. Variation from the beginning to the study end of hormonal parameter [16 weeks]

      Leptin, resistin, adiponectin and glucagon-like peptide -1.

    6. Variation from the beginning to the study end of uremic toxins produced in the intestinal tract [16 weeks]

      p-cresyl sulfate, indoxyl sulfate and trimethylamine -N-oxide

    7. Variation from the beginning to the study end of nutritional status [16 weeks]

      Serum albumin

    8. Variation from the beginning to the study end of parameters of well-being [16 weeks]

      patient reported health (SF-36).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Stable hemodialysis patients treated by renal replacement therapy for at least 6 months

    • Written informed consent written

    Exclusion Criteria:
    • Patients with malnutrition, infections, carcinoma, previous renal transplant, intestinal diseases (medically diagnosed irritable bowel syndrome, Crohn's disease, ulcerative colitis and diarrhea) and antibiotic treatment within one month of study will be excluded.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Azienda Sanitaria ASL Avellino 2

    Investigators

    • Principal Investigator: Biagio Di Iorio, Chief, PhD, ASL AVELLINO

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Dr Biagio Di Iorio, Dr, Chief Nephrology Division, Azienda Sanitaria ASL Avellino 2
    ClinicalTrials.gov Identifier:
    NCT02976688
    Other Study ID Numbers:
    • ASL AVELLINO
    First Posted:
    Nov 29, 2016
    Last Update Posted:
    Nov 29, 2016
    Last Verified:
    Nov 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Dr Biagio Di Iorio, Dr, Chief Nephrology Division, Azienda Sanitaria ASL Avellino 2
    Endstage renal Disease
    Hemodialysis
    Additional relevant MeSH terms:
    Kidney Diseases
    Kidney Failure, Chronic

    Study Results

    No Results Posted as of Nov 29, 2016